AC Immune (NASDAQ:ACIU) initiated a Phase 1b/2a clinical trial to evaluate its anti-phospho-Tau vaccine in patients with early Alzheimer’s disease (AD).
Targeting pathological Tau, the vaccine is intended as a disease-modifying treatment for AD and other diseases associated with pathological forms of Tau protein.
The trial’s primary objective is to assess the safety, tolerability and immunogenicity of different doses of the vaccine in patients with early AD. Exploratory endpoints include notable biomarkers of AD progression.
“Pathological Tau deposits are one of the key hallmarks of AD,” Andrea Pfeifer, AC Immune’s CEO, said in a statement.
“Their characteristic distribution within the brain coincides with clinical symptoms and disease progression. Targeting phospho-Tau is therefore a very promising approach for treating and preventing this debilitating disease,” she added.